Get startedLog in
    Picture of Xbrane Biopharma AB logo

    XBRANE — Xbrane Biopharma AB Income Statement

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Xbrane Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    R2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSPRESSPRESS
    Standards:
    IFRS
    IFRS
    IFRS    		——
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue057.6239148152
    Cost of Revenue
    Gross Profit0—35.413089.5
    Selling / General / Administrative Expenses
    Research And Development
    Other Operating Expenses
    Total Operating Expenses181224561245181
    Operating Profit-181-166-322-97.2-28.2
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-183-169-322-130-43.9
    Provision for Income Taxes
    Net Income After Taxes-183-169-322-141-46.2
    Minority Interest
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income-188-173-388-266127
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-188-173-388-266127
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-110-93.4-19,872-11.5-2.24
    Dividends per Share